Our Research Lead examined anonymized platform data from: 5,864 US adults using tirzepatide (Mounjaro or Zepbound) 4,456 US adults using semaglutide (Ozempic or Wegovy) Inclusion criteria: Active GLP-1 therapy with weekly injections Minimum 12-week tracking duration Adherence threshold: 1 injection log and 1 weight entry per week No weight entries outside physiological bounds (30300 kg) or with weekly changes exceeding 5% Primary outcome: Percentage body weight change from baseline, calculated as [(current weight baseline weight) / baseline weight] 100 , where negative values indicate weight loss Data collection period: Data were collected from all available platform records through January 2026, representing naturalistic use patterns without researcher intervention
Ozempics manufacturer, Novo Nordisk, has not objected to the application to consolidate cases, so we believe an MDL is likely
As semaglutide reaches therapeutic levels and you continue working through the titration schedule, weight loss typically resumes
The purpose of this study was to determine if GLP-RAs can reduce the risk of lymphedema in patients undergoing ALND
Additionally, prednisone can exacerbate existing conditions like diabetes and hypertension, making careful medical supervision essential during treatment.Warnings Were Here To Help You Find Your Way Would you like more information about mental health or drug addiction